Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
For an overview of all press releases in connection with the Negma financing agreement, please go to Convertible bonds.
Mendus announces positive data from the ALISON trial in ovarian cancer presented at the AACR Annual Meeting 2023
VIDIDENCEL INDUCES DURABLE VACCINE-INDUCED T-CELL RESPONSES IN THE MAJORITY OF PATIENTS Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor...